Phase III, multicenter, randomized, open, positive-drug parallel control trial evaluating the efficacy and safety of injectable recombinant human parathyroid hormone (1-34) [56.5 µg] (SAL056) in postmenopausal women with osteoporosis at high risk of fracture
A randomized Crossover TrIal to Compare recombinant human rhPTH(1-34) to the ASsociation alfacalcidol/hydrochlorothiazide in the treatment of Autosomal Dominant Hypocalcemia - ACTICAS
Effect of PTH(1-34) Treatment on Fracture Healing in Vivo
The purpose of the study is to investigate, whether PTH(1-34) is able to promote fracture healing in postmenopausal women with fractures of the hip or shoulder.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.